Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2006 2
2007 5
2008 5
2009 3
2011 2
2012 2
2013 2
2014 8
2015 5
2016 7
2017 10
2018 7
2019 9
2020 7
2021 19
2022 9
2023 10
2024 8
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Lung Cancer in the Republic of Ireland.
Keogh RJ, Barr MP, Keogh A, McMahon D, Baird AM, Cotter S, Breen D, Fitzmaurice GJ, Fitzpatrick D, O'Brien C, Finn SP, Naidoo J. Keogh RJ, et al. Among authors: finn sp. J Thorac Oncol. 2023 Jul;18(7):851-857. doi: 10.1016/j.jtho.2023.03.027. J Thorac Oncol. 2023. PMID: 37348994 Free article. No abstract available.
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S, Loi S, André F, Chandarlapaty S, Felip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, Stahel RA. Peters S, et al. Among authors: finn sp. Ann Oncol. 2024 Jul;35(7):607-629. doi: 10.1016/j.annonc.2024.04.002. Epub 2024 Apr 20. Ann Oncol. 2024. PMID: 38648979 Free article. Review.
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.
Haberecker M, Rüschoff JH, Andriakopoulou C, Gray SG, Nackaerts K, De Perrot M, Brcic L, Nadal E, Tsimpoukis S, Ampollini L, Aerts JG, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, Von Der Thüsen J, Vagenknecht P, Tsourti Z, Kerr KM, Kammler R, Peters S, Baas P, Opitz I, Stahel RA, Curioni-Fontecedro A; ETOP Mesoscape Consortium. Haberecker M, et al. Among authors: finn sp. JCO Precis Oncol. 2025 Feb;9:e2400675. doi: 10.1200/PO-24-00675. Epub 2025 Feb 12. JCO Precis Oncol. 2025. PMID: 39938010
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thüsen J, Marti N, Vervita K, Kammler R, Peters S, Stahel RA, Baas P, Opitz I; ETOP Mesoscape consortium. Rüschoff JH, et al. Among authors: finn sp. Mod Pathol. 2022 Dec;35(12):2033. doi: 10.1038/s41379-022-01170-z. Mod Pathol. 2022. PMID: 36253399 Free PMC article. No abstract available.
Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression.
Huang L, Winter SJ, Olsson LT, Hamilton AM, Halliday SR, Kirk EL, Farnan L, Gerstel A, Craig SG, Finn SP, LaBonte Wilson M, Jain S, Troester MA, Butler EN, Bensen JT, Wobker SE, Allott EH. Huang L, et al. Among authors: finn sp. Cancer Epidemiol Biomarkers Prev. 2024 Dec 2;33(12):1623-1632. doi: 10.1158/1055-9965.EPI-24-0263. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 39269980
Circular RNAs: Biogenesis, Function and Role in Human Diseases.
Greene J, Baird AM, Brady L, Lim M, Gray SG, McDermott R, Finn SP. Greene J, et al. Among authors: finn sp. Front Mol Biosci. 2017 Jun 6;4:38. doi: 10.3389/fmolb.2017.00038. eCollection 2017. Front Mol Biosci. 2017. PMID: 28634583 Free PMC article. Review.
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: finn sp. Clin Cancer Res. 2024 Nov 15;30(22):5180-5191. doi: 10.1158/1078-0432.CCR-24-0932. Clin Cancer Res. 2024. PMID: 39250635 Clinical Trial.
115 results